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group. However, there is no signiﬁcant difference between
the costs of bone fracture in older women with early
breast cancer and older women who do not have breast
cancer.
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OBJECTIVES: The decision to decide for operating liver
metastases in colorectal cancer (CRC) patients depends
largely on the performance of imaging techniques. A more
sensitive and speciﬁc test is only of value when it induces
a change in therapeutical decisions. This study aimed at
analysing the health economic impact of Resovist®, a
superparamagnetic iron oxide used in magnetic resonance
imaging (MRI) for the diagnosis of hepatic CRC metas-
tases. The selected setting was Belgium. METHODS: A
medical decision tree model simulating a patient’s evolu-
tion applying a 5-year time horizon was developed using
2 scenarios; 1) current diagnostic algorithms; and 2)
Resovist® added to current algorithms). Clinical data
reveal that, in comparison to current diagnosis Resovist®
offers an increased sensitivity (95.4 vs. 74.3 %) and a
moderately increased speciﬁcity (89.4 vs. 86.2 %), and
such an improved test performance would change medical
management in about 30% of patients. A Delphi panel
with 16 members indicated that this change in practice
would be in 29 % from no operation to operation and in
71% from operation to no operation. The Delphi panel
also provided medical resource use data. Costs of medical
resources were obtained from the public health insurance.
Life expectancy in function of chosen medical action was
obtained from epidemiological literature. RESULTS:
Resovist® increased costs with €655.4, and adds 1.32
months to life resulting in a cost-effectiveness = €5958 per
Life Year Gained, which means good value for money.
Sensitivity analysis (20% up and down) on performance
of the diagnostic tool, cost of treatment options and
change in medical practice showed robustness of the con-
clusions with a maximal range from €3527 to €10,032.
CONCLUSION: This medical decision tree approach
showed that Resovist® has the potential to improve
medical management and outcomes at a very acceptable
ratio between costs and effects.
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OBJECTIVES: Since May 2001, vinorelbine has been
available to be administered in oral form at home in the
treatment of non-small cell lung cancer. Its efﬁcacy is
similar to that of IV vinorelbine, gastro-intestinal toxic-
ity is more frequent. The periodicity of the treatment
follow up in a hospital environment is poorly deﬁned.
The aim of this study is to establish the regimen, which
minimises costs whilst ensuring patient safety. ME-
THODS: A model was constructed in order to follow 
the repercussions of attending hospital every 3, 6, or 9
weeks compared to purely outpatient, weekly manage-
ment. The corresponding costs were compared to those
of conventional treatments used in the indication: 
gemcitabine, docetaxel and paclitaxel. Costs were esti-
mated from the society perspective. For hospital courses,
the DRG costs were adjusted by replacing the drugs com-
ponent by the actual cost of the substances. For the oral
form, primary care costs are allocated values using the
price of oral form and the primary care visit or an hos-
pital specialist consultation. RESULTS: For equivalent
therapeutic efﬁcacy, oral vinorelbine appears to be the
least expensive substance: its annual follow up costs 
per patient using specialised consultations every 3, 6, 
and 9 weeks were €6360, €6190, and €5940. The least
expensive regimen was the regimen involving entirely
home management following initial day hospitalisation:
€5940. IV cytotoxic agents administered in hospital: gem-
citabine, vinorelbine, docetaxel and paclitaxel had annual
follow up costs of 6970, €7400, €8320, and €9440
respectively. CONCLUSION: How can patient safety and
the will to keep a patient at home at the end of their life
be reconciled? An economic analysis can quantify the
ﬁnancial repercussions of the more or less extensive inter-
pretations which clinicians place on the principle of 
precaution.
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Capecitabine (Xeloda®) was the ﬁrst oral oncology drug
launched on the French market for the management of
metastatic colorectal cancer patients. This drug gives the
opportunity to caregivers to treat cancer on an outpatient
basis. OBJECTIVE: Assess the economic impact of
capecitabine compared with the FuFol/Mayo Clinic
chemotherapy regimen in metastatic colorectal cancer
from the French payer’s perspective. METHODS: A RCT
(SO 14796) demonstrated an equivalent efﬁcacy of the
two therapeutic strategies. Based on this clinical data, a
cost minimisation analysis was carried out. Costs were
assessed for hospitalisation, chemotherapy regimen
administration, management of adverse events and
patient monitoring. All these costs, with the exception 
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of capecitabine administration cost, were derived from
DRG information issued by French Health Authorities.
For capecitabine, the administration cost (drug acquisi-
tion cost excluded) has been considered to be equal to 
the cost of an oncologist out-patient visit. RESULTS:
Efﬁcacy was assessed for 297 patients in the capecitabine
arm and for 299 patients in the FuFol arm based on 
an average follow-up of 165 days. The average costs for 
the management of metastatic colorectal cancer patients
with capecitabine and FuFol are respectively €4320 and
€10,311 (p < 0.001). Full administration costs (corre-
sponding to the drug acquisition cost plus the cost related
to the administration) are €3882 for capecitabine and
€9742 for FuFol (p < 0.001). Costs related to the treat-
ment of adverse events are €396 for capecitabine and
€537 for FuFol (p = 0.16). CONCLUSION: This cost
minimisation analysis shows that the use of capecitabine
results in very signiﬁcant savings on ﬁxed costs. Hospital
medical resources are becoming particularly scarce in
France. In this context, capecitabine is of high economic
interest for the treatment of metastatic colorectal cancer.
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OBJECTIVES: Evaluating the outcomes of prophylactic
care and estimating direct medical costs of CINV among
patients receiving emetogenic chemotherapy in Germany.
METHODS: Prospective, multi-center, cross-sectional,
cost-of-illness study (3 hospitals and 3 ofﬁce-based facil-
ities). Two hundred eight patients receiving level 4 or 5
emetogenic chemotherapy (Hesketh classiﬁcation) were
evaluable. Data were obtained from chart reviews and
patients’ diaries. We provide data on the subgroup of 137
patients who received chemotherapy at hospital (mean
age: 55 years; 61% male) and present costs from
providers’ perspective (hospital). RESULTS: Seventy-
three patients (53%) reported at least 1 episode of nausea
or vomiting, despite antiemetic prophylaxis. More
patients experienced delayed than acute CINV (50% vs.
20%) and more patients reported nausea than vomiting
(51% vs. 21%). Ninety percent and 71% of patients
received prophylactic antiemetic regimens for acute or
delayed CINV in compliance with ASCO (American
Society of Clinical Oncology) guidelines, respectively.
Twelve percent of patients receiving prophylaxis for
delayed symptoms according to ASCO guidelines experi-
enced delayed vomiting in contrast to 34% of the group
whose treatment did not follow the guidelines (p < 0.05).
One patient was rehospitalized due to CINV; 12 patients
received rescue medication at hospital. Mean direct
medical costs for antiemetic prophylaxis per patient and
treatment cycle were €34 (SD 11). Mean direct costs due
to CINV per patient and cycle were €15 (SD 81). Staff
time and material consumption associated with manag-
ing episodes of CINV was the main cost driver (92%).
Rescue medication (administered inside hospital) is
responsible for 8% of those costs. CONCLUSIONS: In
the hospital setting we found considerable room for
improvement in processes and outcomes of care regard-
ing guideline adherence for antiemetic prophylaxis of
delayed CINV. Aside from its clinical consequences,
CINV has an additional economic impact in oncology
centers. Improved CINV prophylaxis may potentially
offset some of costs of CINV treatment.
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OBJECTIVE: To estimate costs associated with manage-
ment of chemotherapy-induced toxicity with pemetrexed
compared with docetaxel as second-line chemotherapy
for advanced non-small cell lung cancer (NSCLC).
METHODS: Resource utilization data were analysed
from a multinational phase III randomised trial compar-
ing pemetrexed (ALIMTA®) with docetaxel (N = 571).
Costs included in this initial analysis were hospitalisa-
tions, transfusions, erythropoietin, granulocyte colony-
stimulating factors (GCSFs) and parenteral antibiotics.
Unit costs were sourced from UK National Health Service
(NHS) case mix data (2002) and national drug prices.
RESULTS: Efﬁcacy was shown to be similar with median
survival times of approximately 8 months for both arms,
although toxicity-related events and need for medical
management were lower for pemetrexed. CTC grade 3/4
neutropenia and neutropenic fever were signiﬁcantly
higher for docetaxel (40% vs. 5%, 13% vs. 2%, respec-
tively). Most other grade 3/4 toxicities, including
nausea/vomiting, diarrhoea, thrombocytopenia and
anaemia, occurred at low rates (£5%) and were similar
between treatment arms. The most common reasons for
drug-related hospitalisation for both arms were febrile
neutropenia and neutropenia (4 admissions on the peme-
trexed arm [£4730] vs. 42 on the docetaxel arm
